Protocol Ledger

NCT03428477 · Phase III · ACTIVE NOT RECRUITING

EPA for Metastasis Trial 2

Interventional Phase III clinical trial protocol NCT03428477 sponsored by Mark A Hull, PhD FRCP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-02 Enrollment: 418 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03428477
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)418 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03428477
Protocol FieldVerified Registry Value
NCT IdentifierNCT03428477
Consolidated Lead SponsorMark A Hull, PhD FRCP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment418 participants (ACTUAL)
Registered Start Date2018-05-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03428477
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
Nottingham University Hospitals NHS TrustNottingham, United KingdomOpen Hospital Dossier ->
University Hospital Southampton NHS Foundation TrustSouthampton, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI